The overall goal of the Transfusion Medicine/Hemostasis Clinical Trials Network (TMH CTN) is to conduct multi-center clinical studies to evaluate treatments and management strategies for children and adults with hemostatic disorders and methods of transfusion support for a variety of patient populations. The New England Research Institutes, Inc. (NERI) will continue to support the TMH CTN as Data Coordinating Center (DCC). The DCC has the following aims: 1) to collaborate in the selection, design, conduct, analysis and reporting of clinical studies and trials;2) to develop a mechanism for patient recruitment and retention from out-of-network centers;3) to manage protocol fund disbursement to both core and non-core sites;4) to develop and maintain a data management system for each network study;5) to institute quality control procedures including training site study personnel and conducting site visits;6) to identify central laboratories and central review panels, and develop a system for tracking lab specimens and results;7) to compile, edit, analyze and report study data;and 8) to coordinate the activities and meetings of the Steering Committee, and provide materials for PRC and DSMB members. During its first four years, the network has begun 3 clinical trials, and has 4 other studies nearing the final stages of development. These ongoing and planned studies include adjudication of specific clinical eligibility criteria and endpoints, a central ultrasound reading facility, and several central laboratories. The Transfusion Medicine/Hemostasis Clinical Trials Network will have an impact on the standard of care by investigating the efficacy, safety, and healthcare policy implications of treatment strategies in transfusion medicine and hematology. Conducting multicenter clinical trials within this network will provide sufficient subjects to evaluate important hypotheses regarding therapy and management in the respective patient populations. Study findings will be disseminated to the medical and scientific communities. The Transfusion Medicine/Hemostasis Clinical Trials Network plans and carries out studies in two areas of medicine. Transfusion Medicine studies investigate which patients need to be treated by giving transfusions, and which types and doses of transfusions to give. Hemostasis studies investigate disorders that put people at increased risk for serious bleeding or blood clots, and how to treat these disorders.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-J (M1))
Program Officer
Mondoro, Traci
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New England Research Institute
United States
Zip Code
Leissinger, C; Josephson, C D; Granger, S et al. (2014) Rituximab for treatment of inhibitors in haemophilia A. A Phase II study. Thromb Haemost 112:445-58
Triulzi, Darrell J; Assmann, Susan F; Strauss, Ronald G et al. (2012) The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood 119:5553-62
Josephson, Cassandra D; Granger, Suzanne; Assmann, Susan F et al. (2012) Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Blood 120:748-60
Lehmann, Harold P; Dambita, Nkossi; Buchanan, George R et al. (2011) Decision modeling of disagreements: pediatric hematologists' management of idiopathic thrombocytopenic purpura. Med Decis Making 31:805-15
Slichter, Sherrill J; Kaufman, Richard M; Assmann, Susan F et al. (2010) Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 362:600-13
Steiner, M E; Assmann, S F; Levy, J H et al. (2010) Addressing the question of the effect of RBC storage on clinical outcomes: the Red Cell Storage Duration Study (RECESS) (Section 7). Transfus Apher Sci 43:107-16
Slichter, Sherrill J (2006) Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. J Clin Apher 21:78-84
Segal, Jodi B; Dzik, Walter H; Transfusion Medicine/Hemostasis Clinical Trials Network (2005) Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 45:1413-25